Optimization of scAAVIL-1ra in vitro and in vivo to deliver high levels of therapeutic protein for treatment of osteoarthritis

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e70-

  Goodrich, Laurie R ^a   Phillips, Jennifer N ^a   McIlwraith, C Wayne ^a   Foti, Stacey B ^b   Grieger, Joshua C ^b   Gray, Steven J ^b   Samulski, R Jude ^b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

IL 1ra; Intraarticular; Joints and arthroscopy; ScAAV

Indexed keywords

ADENOVIRUS VECTOR; BETA ACTIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SELF COMPLEMENTARY ADENO ASSOCIATED VIRUS VECTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CHIMERA; CLONING; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG INHIBITION; ENDOSCOPY; FLUORESCENCE MICROSCOPY; GENE CASSETTE; GENE CONSTRUCT; GENE EXPRESSION; GENE SEQUENCE; GENE TRANSFER; HORSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; SEROTYPE; SYNOVIAL FLUID; TOXICITY; TRANSGENE; VIRAL GENE THERAPY; VIRUS CAPSID;

EID: 84878834158     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.61     Document Type: Article

References (55)

1. Daheshia, M and Yao, JQ (2008). The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol 35: 2306-2312.
2. Buckwalter, JA and Brown, TD (2004). Joint injury, repair, and remodeling: roles in posttraumatic osteoarthritis. Clin Orthop Relat Res: 7-16. (Pubitemid 38787709)
3. Dinarello, CA and Thompson, RC (1991). Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12: 404-410.
4. Kivitz, A, Eisen, G, Zhao, WW, Bevirt, T and Recker, DP (2002). Randomized placebocontrolled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 51: 530-537. (Pubitemid 34602987)
5. Simon, LS, Lanza, FL, Lipsky, PE, Hubbard, RC, Talwalker, S, Schwartz, BD et al. (1998). Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41: 1591-1602. (Pubitemid 28459917)
6. McGettigan, P and Henry, D (2006). Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633-1644. (Pubitemid 44511610)
7. Barnhill, JG, Fye, CL, Williams, DW, Reda, DJ, Harris, CL and Clegg, DO (2006). Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial. J Am Pharm Assoc (2003) 46: 14-24. (Pubitemid 46037381)
8. Clegg, DO, Reda, DJ, Harris, CL, Klein, MA, O'Dell, JR, Hooper, MM et al. (2006). Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354: 795-808. (Pubitemid 43290918)
9. Michel, BA, Stucki, G, Frey, D, De Vathaire, F, Vignon, E, Bruehlmann, P et al. (2005). Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 52: 779-786. (Pubitemid 40365099)
10. Uebelhart, D, Malaise, M, Marcolongo, R, de Vathaire, F, DeVathaire, F, Piperno, M et al. (2004). Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a oneyear, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil 12: 269-276. (Pubitemid 38461289)
11. Frisbie, DD, Kawcak, CE, McIlwraith, CW and Werpy, NM (2009). Evaluation of polysulfated glycosaminoglycan or sodium hyaluronan administered intra-articularly for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res 70: 203-209.
12. Arend, WP (1993). Interleukin-1 receptor antagonist. Adv Immunol 54: 167-227. (Pubitemid 23289253)
13. Arend, WP, Welgus, HG, Thompson, RC and Eisenberg, SP (1990). Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 85: 1694-1697. (Pubitemid 20176469)
14. Firestein, GS, Berger, AE, Tracey, DE, Chosay, JG, Chapman, DL, Paine, MM et al. (1992). IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 149: 1054-1062.
15. Yang, KG, Raijmakers, NJ, van Arkel, ER, Caron, JJ, Rijk, PC, Willems, WJ et al. (2008). Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthr Cartil 16: 498-505. (Pubitemid 351444567)
16. Frisbie, DD, Kawcak, CE, Werpy, NM, Park, RD and McIlwraith, CW (2007). Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 68: 290-296. (Pubitemid 46487515)
17. Goodrich, LR, Brower-Toland, BD, Warnick, L, Robbins, PD, Evans, CH and Nixon, AJ (2006). Direct adenovirus-mediated IGF-I gene transduction of synovium induces persisting synovial fluid IGF-I ligand elevations. Gene Ther 13: 1253-1262. (Pubitemid 44264079)
18. Frisbie, DD, Ghivizzani, SC, Robbins, PD, Evans, CH and McIlwraith, CW (2002). Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 9: 12-20. (Pubitemid 34145163)
19. Kay, JD, Gouze, E, Oligino, TJ, Gouze, JN, Watson, RS, Levings, PP et al. (2009). Intraarticular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med 11: 605-614.
20. Evans, CH, Robbins, PD, Ghivizzani, SC, Wasko, MC, Tomaino, MM, Kang, R et al. (2005). Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 102: 8698-8703. (Pubitemid 40862798)
21. Payne, KA, Lee, HH, Haleem, AM, Martins, C, Yuan, Z, Qiao, C et al. (2011). Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees. Osteoarthr Cartil 19: 1058-1065.
22. Bandara, G, Mueller, GM, Galea-Lauri, J, Tindal, MH, Georgescu, HI, Suchanek, MK et al. (1993). Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 90: 10764-10768. (Pubitemid 23347123)
23. Gouze, E, Pawliuk, R, Pilapil, C, Gouze, JN, Fleet, C, Palmer, GD et al. (2002). In vivo gene delivery to synovium by lentiviral vectors. Mol Ther 5: 397-404. (Pubitemid 34308664)
24. Nixon, AJ, Goodrich, LR, Scimeca, MS, Witte, TH, Schnabel, LV, Watts, AE et al. (2007). Gene therapy in musculoskeletal repair. Ann N Y Acad Sci 1117: 310-327. (Pubitemid 350191284)
25. Pan, RY, Chen, SL, Xiao, X, Liu, DW, Peng, HJ and Tsao, YP (2000). Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 43: 289-297. (Pubitemid 30395737)
26. Ishihara, A, Bartlett, JS and Bertone, AL (2012). Inflammation and immune response of intra-articular serotype 2 adeno-associated virus or adenovirus vectors in a large animal model. Arthritis 2012: 735472.
27. Goodrich, LR, Choi, VW, Carbone, BA, McIlwraith, CW and Samulski, RJ (2009). Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adenoassociated viral vectors. Hum Gene Ther 20: 1697-1702.
28. Sun, J, Hakobyan, N, Valentino, LA, Feldman, BL, Samulski, RJ and Monahan, PE (2008). Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood 112: 4532-4541.
29. Mitchell, AM, Nicolson, SC, Warischalk, JK and Samulski, RJ (2010). AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther 10: 319-340.
30. Ortolano, S, Spuch, C and Navarro, C (2012). Present and future of adeno associated virus based gene therapy approaches. Recent Pat Endocr Metab Immune Drug Discov 6: 47-66.
31. Byers, S, Rothe, M, Lalic, J, Koldej, R and Anson, DS (2009). Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues. Mol Genet Metab 97: 102-108.
32. Frisbie, DD, Kawcak, CE, Werpy, NM, Park, RD and McIlwraith, CW (2007). Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 68: 290-296. (Pubitemid 46487515)
33. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
34. Gouze, E, Gouze, JN, Palmer, GD, Pilapil, C, Evans, CH and Ghivizzani, SC (2007). Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases. Mol Ther 15: 1114-1120. (Pubitemid 46813614)
35. Frisbie, DD and McIlwraith, CW (2000). Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis. Clin Orthop Relat Res (suppl. 379): S273-S287.
36. Izal, I, Acosta, CA, Ripalda, P, Zaratiegui, M, Ruiz, J and Forriol, F (2008). IGF-1 gene therapy to protect articular cartilage in a rat model of joint damage. Arch Orthop Trauma Surg 128: 239-247. (Pubitemid 351167220)
37. Boissier, MC, Lemeiter, D, Clavel, C, Valvason, C, Laroche, L, Begue, T et al. (2007). Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype. Hum Gene Ther 18: 525-535. (Pubitemid 47036046)
38. Hu, C and Lipshutz, GS (2012). AAV-based neonatal gene therapy for hemophilia A: longterm correction and avoidance of immune responses in mice. Gene Ther 19: 1166-1176.
39. Bell, P, Wang, L, Gao, G, Haskins, ME, Tarantal, AF, McCarter, RJ et al. (2011). Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. Mol Genet Metab 104: 395-403.
40. Gray, SJ, Foti, SB, Schwartz, JW, Bachaboina, L, Taylor-Blake, B, Coleman, J et al. (2011). Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 22: 1143-1153.
41. Mease, PJ, Wei, N, Fudman, EJ, Kivitz, AJ, Schechtman, J, Trapp, RG et al. (2010). Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase Study. J Rheumatol 37: 692-703.
42. Ghivizzani, SC, Lechman, ER, Kang, R, Tio, C, Kolls, J, Evans, CH et al. (1998). Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 95: 4613-4618. (Pubitemid 28207961)
43. Whalen, JD, Lechman, EL, Carlos, CA, Weiss, K, Kovesdi, I, Glorioso, JC et al. (1999). Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 162: 3625-3632. (Pubitemid 29313617)
44. Miagkov, AV, Kovalenko, DV, Brown, CE, Didsbury, JR, Cogswell, JP, Stimpson, SA et al. (1998). NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 95: 13859-13864. (Pubitemid 28523063)
45. Kim, SH, Lechman, ER, Kim, S, Nash, J, Oligino, TJ and Robbins, PD (2002). Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 6: 591-600. (Pubitemid 35363691)
46. Lechman, ER, Jaffurs, D, Ghivizzani, SC, Gambotto, A, Kovesdi, I, Mi, Z et al. (1999). Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol 163: 2202-2208. (Pubitemid 29382228)
47. Ishihara, AB and Bertone, AL. (2010). Biologic response to intra-articular Ad/AAV BMP2 vectors. 56th Annual Meeing of the Orthopaedic Research Society, New Orleans.
48. McCarty, DM, Monahan, PE and Samulski, RJ (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8: 1248-1254. (Pubitemid 32780813)
49. Xiao, X, Li, J and Samulski, RJ (1998). Production of high-titer recombinant adenoassociated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232. (Pubitemid 28100780)
50. Rabinowitz, JE, Rolling, F, Li, C, Conrath, H, Xiao, W, Xiao, X et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 791-801. (Pubitemid 34033377)
51. Bowles, DE, McPhee, SW, Li, C, Gray, SJ, Samulski, JJ, Camp, AS et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20: 443-455.
52. McCarty, DM, Fu, H, Monahan, PE, Toulson, CE, Naik, P and Samulski, RJ (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10: 2112-2118. (Pubitemid 37536760)
53. Grieger, JC, Choi, VW and Samulski, RJ (2006). Production and characterization of adeno-associated viral vectors. Nat Protoc 1: 1412-1428.
54. Nixon, AJ, Lust, G and Vernier-Singer, M (1992). Isolation, propagation, and cryopreservation of equine articular chondrocytes. Am J Vet Res 53: 2364-2370.
55. Gray, SJ, Matagne, V, Bachaboina, L, Yadav, S, Ojeda, SR and Samulski, RJ (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19: 1058-1069.